Treatment Outcome of Low-dose Interleukin-2 Therapy in Patients with Metastatic Renal Cell Carcinoma

Renal cell carcinoma (RCC) is one of the most fatal urological malignancies. Approximately 30% of patients with RCC have metastasis at initial diagnosis and another 30% have metastasis after radical nephrectomy. Immunotherapy using interferon-α (IFN-α) and interleukin-2 (IL-2) has been the main trea...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Anticancer research 2016-09, Vol.36 (9), p.4961-4964
Hauptverfasser:	Takezawa, Yuta, Izumi, Kouji, Shimura, Yusuke, Aerken, Maolake, Natsagdorji, Ariunbold, Iijima, Masashi, Shigehara, Kazuyoshi, Nohara, Takahiro, Narimoto, Kazutaka, Kadono, Yoshifumi, Kitagawa, Yasuhide, Konaka, Hiroyuki, Mizokami, Atsushi
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Carcinoma, Renal Cell - drug therapy Carcinoma, Renal Cell - pathology Carcinoma, Renal Cell - surgery Disease-Free Survival Dose-Response Relationship, Drug Female Humans Interferon-alpha - administration & dosage Interleukin-2 - administration & dosage Male Middle Aged Neoplasm Metastasis Nephrectomy Prognosis Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!